{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 6.5.1.4 PE/PP/IVIg', 'In Table 7 and Table 8, applicable', 'To clarify timing of', 'supplemental dosing day range has been', 'supplemental dosing and to', 'added, and doses and corresponding diluent', 'maintain blind on Day 183.', 'and total volumes have been corrected in the', 'Placebo group Open Label Extension', 'associated with the Blinded ravulizumab', 'loading dose administered on Day 183. Details', 'in text on supplemental dose timing.', 'Section 6.5.1.5 Disallowed', 'Added chronic PE/PP and IVIg therapies.', 'To clarify that only acute', 'Medications and Therapies', 'treatment is permitted.', 'Section 8.1.1 Hospitalization', 'Reduced information to be collected to', 'To reduce burden on patients.', 'include only that required for meaningful', 'assessment.', 'Section 8.1.2 Clinical', 'Replaced text description of PK/PD sampling', 'Clarification. Specific order', 'Deterioration', 'during Clinical Deterioration with a figure that', 'of procedures is not required.', 'provides instructions more clearly. Changed', 'numbering to bullets.', 'Section 8.1.9 MGFA Clinical', 'Added new section describing Day 1', 'Correction.', 'Classification', 'assessment of MGFA Clinical Classification.', 'Section 8.1.10 MGFA Post-', 'Noted that modified version of MGFA-PIS', 'Clarification.', 'Intervention Status', 'does not include categories of Exacerbation or', 'Died of MG.', 'Section 8.2.3', 'Indicated that QT interval will be corrected for', 'Clarification.', 'Electrocardiogram', \"heart rate using Fridericia's formula.\", 'Section 8.2.4.1 Urinalysis and', 'Removed statement regarding', 'Correction.', 'Urine Chemistry', 'protein:creatinine ratio, which will not be', 'performed in this study.', 'Section 8.2.5.1 Columbia-', 'Added timepoints (lifetime and past 1 year [12', 'To provide specific time', 'Suicidal Severity Rating Scale', 'months]) for assessing suicidal ideation and', 'points for data collection that', 'behaviors', 'have been implemented in the', 'eCRF.', 'Section 8.3.1 Time Period and', 'All adverse events that occur after the', 'To ensure appropriate', 'Frequency for Collecting', 'informed consent form (ICF) is signed must', 'collection of pretreatment', 'Adverse Event and Serious', 'be recorded in the adverse event case report', 'adverse events.', 'Adverse Event Information', 'form, not in the medical history form.', 'Section 8.8 Biomarkers', 'Noted that unused PK/PD/ADA/AChR', 'To allow for future studies to', 'samples may be stored for future biomarker', 'understand drug/disease', 'research.', 'mechanisms.', 'Section 8.9 Healthcare', 'Data collected will be the type of facility', 'To reduce data collection to', 'Resource Utilization', '(hospital, rehabilitation center, or hospice),', 'only those elements needed', 'whether the primary reason for admission was', 'for analysis.', 'related to MG, and the duration of', 'hospitalization.', 'Section 9 Statistical', 'Added description of plans for CSR', 'Clarification.', 'Considerations', 'preparation.', 'Section 9.1 Statistical', 'Re-ordered secondary and exploratory', 'To better characterize disease', 'Hypotheses', 'hypotheses and estimation of treatment effect', 'parameters associated with', 'to align with changes made in Section 1.1 and', 'gMG and yield a clearer', 'Section 3 Objectives and Endpoints.', 'assessment of the impact of', 'study intervention.', 'Section 9.4.5.4 Multiplicity', 'Added description of secondary hypothesis', 'To inform on statistical', 'Adjustment for Primary and', 'testing.', 'methods.', 'Secondary Endpoints', 'Page 6 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9.4.6.4 Analysis of PK', 'Revised description of analyses to be', 'To inform on statistical', 'and PD', 'performed.', 'methods.', 'Section 10.1.3 Data Protection', 'Described storage of anonymized data.', 'To inform on data protection.', 'Section 10.2 Appendix 2:', 'Deleted creatinine and added leukocyte', 'Correction.', 'Clinical Laboratory Tests', 'esterase, ADA, and AChR Ab.', 'Section 10.8 Appendix 8', 'Replaced with updated image.', 'Correction.', 'Myasthenia Gravis Composite', 'Scale', 'Section 10.11 Appendix 11:', 'The last 3 questions of the Neurology Quality', 'Page 2 of the sample', 'Neurology Quality of Life', 'of Life Fatigue questionnaire were added to', 'document was missing in', 'Fatigue', 'Appendix 11.', 'prior versions of the protocol.', 'Section 10.12 Appendix 12:', 'MGFA clinical classification is added as', 'In this trial, MGFA', 'Myasthenia Gravis Foundation', 'Appendix 12.', 'classification is utilized to', 'of America Clinical', 'assess the MG clinical state', 'Classification', 'of patients. It was missing in', 'prior versions of the protocol.', 'Section 10.16 Appendix 16:', 'Expanded description of sample size', 'To inform on statistical', 'Statistical Considerations', 'determination.', 'methods.', 'Page 7 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}